Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276


New insights into nuclear factor erythroid 2-related factors in toxicology and pharmacology.

Pi J, Hayes JD, Yamamoto M.

Toxicol Appl Pharmacol. 2019 Mar 15;367:33-35. doi: 10.1016/j.taap.2019.01.014. Epub 2019 Feb 4. No abstract available.


Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.

Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kensler TW, Dinkova-Kostova AT.

Nat Rev Drug Discov. 2019 Apr;18(4):295-317. doi: 10.1038/s41573-018-0008-x. Review.


Zinc-binding triggers a conformational-switch in the cullin-3 substrate adaptor protein KEAP1 that controls transcription factor NRF2.

McMahon M, Swift SR, Hayes JD.

Toxicol Appl Pharmacol. 2018 Dec 1;360:45-57. doi: 10.1016/j.taap.2018.09.033. Epub 2018 Sep 24.


Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).

Sharma RS, Harrison DJ, Kisielewski D, Cassidy DM, McNeilly AD, Gallagher JR, Walsh SV, Honda T, McCrimmon RJ, Dinkova-Kostova AT, Ashford MLJ, Dillon JF, Hayes JD.

Cell Mol Gastroenterol Hepatol. 2017 Dec 13;5(3):367-398. doi: 10.1016/j.jcmgh.2017.11.016. eCollection 2018 Mar.


A partnership with the proteasome; the destructive nature of GSK3.

Robertson H, Hayes JD, Sutherland C.

Biochem Pharmacol. 2018 Jan;147:77-92. doi: 10.1016/j.bcp.2017.10.016. Epub 2017 Nov 1. Review.


Epigenetic Control of NRF2-Directed Cellular Antioxidant Status in Dictating Life-Death Decisions.

Hayes JD, Dinkova-Kostova AT.

Mol Cell. 2017 Oct 5;68(1):5-7. doi: 10.1016/j.molcel.2017.09.023.


Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.

Torrente L, Sanchez C, Moreno R, Chowdhry S, Cabello P, Isono K, Koseki H, Honda T, Hayes JD, Dinkova-Kostova AT, de la Vega L.

Oncogene. 2017 Nov 2;36(44):6204-6212. doi: 10.1038/onc.2017.221. Epub 2017 Jul 10.


Characterization of liver injury, oval cell proliferation and cholangiocarcinogenesis in glutathione S-transferase A3 knockout mice.

Crawford DR, Ilic Z, Guest I, Milne GL, Hayes JD, Sell S.

Carcinogenesis. 2017 Jul 1;38(7):717-727. doi: 10.1093/carcin/bgx048.


Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.

MacLeod AK, Acosta-Jimenez L, Coates PJ, McMahon M, Carey FA, Honda T, Hayes JD, Henderson CJ, Wolf CR.

Br J Cancer. 2017 Aug 22;117(5):e1. doi: 10.1038/bjc.2017.80. Epub 2017 Mar 21.


Nrf2-Mediated Neuroprotection Against Recurrent Hypoglycemia Is Insufficient to Prevent Cognitive Impairment in a Rodent Model of Type 1 Diabetes.

McNeilly AD, Gallagher JR, Dinkova-Kostova AT, Hayes JD, Sharkey J, Ashford ML, McCrimmon RJ.

Diabetes. 2016 Oct;65(10):3151-60. doi: 10.2337/db15-1653. Epub 2016 Jul 13.


The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic.

O'Connell MA, Hayes JD.

Biochem Soc Trans. 2015 Aug;43(4):687-9. doi: 10.1042/BST20150069. Epub 2015 Aug 3.


Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of β-TrCP and GSK-3.

Hayes JD, Chowdhry S, Dinkova-Kostova AT, Sutherland C.

Biochem Soc Trans. 2015 Aug;43(4):611-20. doi: 10.1042/BST20150011. Epub 2015 Aug 3. Review.


Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.

Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, Hayes JD.

Free Radic Biol Med. 2015 Nov;88(Pt B):108-146. doi: 10.1016/j.freeradbiomed.2015.06.021. Epub 2015 Jun 27. Review.


Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2.

Bell KF, Al-Mubarak B, Martel MA, McKay S, Wheelan N, Hasel P, Márkus NM, Baxter P, Deighton RF, Serio A, Bilican B, Chowdhry S, Meakin PJ, Ashford ML, Wyllie DJ, Scannevin RH, Chandran S, Hayes JD, Hardingham GE.

Nat Commun. 2015 May 13;6:7066. doi: 10.1038/ncomms8066.


Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.

Agathanggelou A, Weston VJ, Perry T, Davies NJ, Skowronska A, Payne DT, Fossey JS, Oldreive CE, Wei W, Pratt G, Parry H, Oscier D, Coles SJ, Hole PS, Darley RL, McMahon M, Hayes JD, Moss P, Stewart GS, Taylor AM, Stankovic T.

Haematologica. 2015 Aug;100(8):1076-85. doi: 10.3324/haematol.2014.115170. Epub 2015 Apr 3.


Transcription factor Nrf1 negatively regulates the cystine/glutamate transporter and lipid-metabolizing enzymes.

Tsujita T, Peirce V, Baird L, Matsuyama Y, Takaku M, Walsh SV, Griffin JL, Uruno A, Yamamoto M, Hayes JD.

Mol Cell Biol. 2014 Oct;34(20):3800-16. doi: 10.1128/MCB.00110-14. Epub 2014 Aug 4.


Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance.

Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, Dinkova-Kostova AT, Dillon JF, Hayes JD, Ashford ML.

Mol Cell Biol. 2014 Sep;34(17):3305-20. doi: 10.1128/MCB.00677-14. Epub 2014 Jun 23.


3-(2-oxoethylidene)indolin-2-one derivatives activate Nrf2 and inhibit NF-κB: potential candidates for chemoprevention.

Nagle AA, Reddy SA, Bertrand H, Tajima H, Dang TM, Wong SC, Hayes JD, Wells G, Chew EH.

ChemMedChem. 2014 Aug;9(8):1763-74. doi: 10.1002/cmdc.201402038. Epub 2014 May 12.


Nrf2 target genes can be controlled by neuronal activity in the absence of Nrf2 and astrocytes.

Deighton RF, Márkus NM, Al-Mubarak B, Bell KF, Papadia S, Meakin PJ, Chowdhry S, Hayes JD, Hardingham GE.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):E1818-20. doi: 10.1073/pnas.1402097111. Epub 2014 Apr 21. No abstract available.


Transcription factor Nrf1 is topologically repartitioned across membranes to enable target gene transactivation through its acidic glucose-responsive domains.

Zhang Y, Ren Y, Li S, Hayes JD.

PLoS One. 2014 Apr 2;9(4):e93458. doi: 10.1371/journal.pone.0093458. eCollection 2014.


The Nrf2 regulatory network provides an interface between redox and intermediary metabolism.

Hayes JD, Dinkova-Kostova AT.

Trends Biochem Sci. 2014 Apr;39(4):199-218. doi: 10.1016/j.tibs.2014.02.002. Epub 2014 Mar 16. Review.


Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy.

Lewerenz J, Baxter P, Kassubek R, Albrecht P, Van Liefferinge J, Westhoff MA, Halatsch ME, Karpel-Massler G, Meakin PJ, Hayes JD, Aronica E, Smolders I, Ludolph AC, Methner A, Conrad M, Massie A, Hardingham GE, Maher P.

Antioxid Redox Signal. 2014 Jun 20;20(18):2907-22. doi: 10.1089/ars.2013.5455. Epub 2014 Feb 6.


A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-κB and Nrf2-Keap1 signaling pathways.

Gan FF, Ling H, Ang X, Reddy SA, Lee SS, Yang H, Tan SH, Hayes JD, Chui WK, Chew EH.

Toxicol Appl Pharmacol. 2013 Nov 1;272(3):852-62. doi: 10.1016/j.taap.2013.07.011. Epub 2013 Jul 27.


RXRα inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2.

Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, Li Y, Li Y, Luo L, Hayes JD, Wang XJ, Tang X.

Cancer Res. 2013 May 15;73(10):3097-108. doi: 10.1158/0008-5472.CAN-12-3386. Epub 2013 Apr 23.


The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613.

Hourihan JM, Kenna JG, Hayes JD.

Antioxid Redox Signal. 2013 Aug 10;19(5):465-81. doi: 10.1089/ars.2012.4944. Epub 2013 Jan 16.


Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity.

Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, Hayes JD.

Oncogene. 2013 Aug 8;32(32):3765-81. doi: 10.1038/onc.2012.388. Epub 2012 Sep 10.


Nrf2 orchestrates fuel partitioning for cell proliferation.

Hayes JD, Ashford ML.

Cell Metab. 2012 Aug 8;16(2):139-41. doi: 10.1016/j.cmet.2012.07.009.


Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis.

Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, Tobón-Velasco JC, Devijver H, García-Mayoral MF, Van Leuven F, Hayes JD, Bertho G, Cuadrado A.

Mol Cell Biol. 2012 Sep;32(17):3486-99. doi: 10.1128/MCB.00180-12. Epub 2012 Jul 2.


Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction.

Hancock R, Bertrand HC, Tsujita T, Naz S, El-Bakry A, Laoruchupong J, Hayes JD, Wells G.

Free Radic Biol Med. 2012 Jan 15;52(2):444-51. doi: 10.1016/j.freeradbiomed.2011.10.486. Epub 2011 Nov 3.


Human embryonic stem cell derived astrocytes mediate non-cell-autonomous neuroprotection through endogenous and drug-induced mechanisms.

Gupta K, Patani R, Baxter P, Serio A, Story D, Tsujita T, Hayes JD, Pedersen RA, Hardingham GE, Chandran S.

Cell Death Differ. 2012 May;19(5):779-87. doi: 10.1038/cdd.2011.154. Epub 2011 Nov 18.


Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents.

Higgins LG, Hayes JD.

Drug Metab Rev. 2011 May;43(2):92-137. doi: 10.3109/03602532.2011.567391. Review.


SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner.

Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A.

Mol Cell Biol. 2011 Mar;31(6):1121-33. doi: 10.1128/MCB.01204-10. Epub 2011 Jan 18.


Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning.

Bell KF, Al-Mubarak B, Fowler JH, Baxter PS, Gupta K, Tsujita T, Chowdhry S, Patani R, Chandran S, Horsburgh K, Hayes JD, Hardingham GE.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):E1-2; author reply E3-4. doi: 10.1073/pnas.1015229108. Epub 2010 Dec 21. No abstract available.


Nrf2, a guardian of healthspan and gatekeeper of species longevity.

Lewis KN, Mele J, Hayes JD, Buffenstein R.

Integr Comp Biol. 2010 Nov;50(5):829-43. doi: 10.1093/icb/icq034. Epub 2010 May 6.


Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals.

McMahon M, Lamont DJ, Beattie KA, Hayes JD.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18838-43. doi: 10.1073/pnas.1007387107. Epub 2010 Oct 18.


Peroxiredoxin gene expression signatures in liver reflect toxic insult.

Young R, Hayes JD, Brown K, Wolf CR, Whitelaw CB.

Assay Drug Dev Technol. 2010 Aug;8(4):512-7. doi: 10.1089/adt.2009.0246.


p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription.

Jain A, Lamark T, Sjøttem E, Larsen KB, Awuh JA, Øvervatn A, McMahon M, Hayes JD, Johansen T.

J Biol Chem. 2010 Jul 16;285(29):22576-91. doi: 10.1074/jbc.M110.118976. Epub 2010 May 7.


Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway.

Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT.

Antioxid Redox Signal. 2010 Dec 1;13(11):1713-48. doi: 10.1089/ars.2010.3221. Epub 2010 Aug 14. Review.


Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para- and ortho-hydroquinones.

Wang XJ, Hayes JD, Higgins LG, Wolf CR, Dinkova-Kostova AT.

Chem Biol. 2010 Jan 29;17(1):75-85. doi: 10.1016/j.chembiol.2009.12.013.


Spatial monitoring of toxicity in HMOX-LacZ transgenic mice.

Young R, Wolf CR, Brown K, Hayes JD, Whitelaw CB.

Transgenic Res. 2010 Oct;19(5):897-902. doi: 10.1007/s11248-010-9363-z. Epub 2010 Jan 14.


Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.

Weber JE, Oakley AJ, Christ AN, Clark AG, Hayes JD, Hall R, Hume DA, Board PG, Smythe ML, Flanagan JU.

Eur J Med Chem. 2010 Feb;45(2):447-54. doi: 10.1016/j.ejmech.2009.10.025. Epub 2009 Oct 23.


Expression and localization of rat aldo-keto reductases and induction of the 1B13 and 1D2 isoforms by phenolic antioxidants.

MacLeod AK, Kelly VP, Higgins LG, Kelleher MO, Price SA, Bigley AL, Betton GR, Hayes JD.

Drug Metab Dispos. 2010 Feb;38(2):341-6. doi: 10.1124/dmd.109.030544. Epub 2009 Nov 17.


Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis.

Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, Hayes JD.

Free Radic Biol Med. 2010 Jan 15;48(2):357-71. doi: 10.1016/j.freeradbiomed.2009.11.007. Epub 2009 Nov 13.


Supplemental Content

Loading ...
Support Center